Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970319 | 0.95 | KDM4E (0.74) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL31156436 | 0.89 | KDM4E (0.74) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL8744889 | 0.87 | NPC1 (0.71) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL9638336 | 0.84 | CYP2C9 (0.87) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL14082284 | 0.84 | KDM4E (0.70) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL806014 | 0.82 | CYP1A2 (1.00) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL5909380 | 0.81 | KDM4E (0.65) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL14382026 | 0.81 | KDM4E (0.63) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL5909377 | 0.81 | KDM4E (0.65) | KDM4ELMNATDP1RAB9ANPC1 | |
| SCHEMBL5909376 | 0.81 | KDM4E (0.65) | KDM4ELMNATDP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9402850-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402850-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-9040567-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040567-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-26 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | KDM4E 192/4885LMNA 692/4885TDP1 1548/4885 |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, BID, BAD | KDM4E 3838/4885LMNA 209/4885TDP1 990/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | KDM4E 861/4885LMNA 624/4885TDP1 2846/4885 |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, ANXA1, BAD | KDM4E 2219/4885LMNA 2505/4885TDP1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.